Sotatercept for pulmonary arterial hypertension: something old and something new
- PMID: 36609525
- DOI: 10.1183/13993003.01972-2022
Sotatercept for pulmonary arterial hypertension: something old and something new
Conflict of interest statement
Conflict of interest: L.J. Rubin reports consultancy fees from Gossamer, Sonivie, Bellerophon and Drug-farm, and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Johnson & Johnson. R. Naeije reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Lung Biotechnology and AOP Orphan Pharmaceuticals, and participation on a data safety monitoring board or advisory board for Johnson & Johnson, AOP Pharmaceuticals, United Therapeutics and Lung Biotechnology.
Comment on
-
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.Eur Respir J. 2023 Jan 6;61(1):2201347. doi: 10.1183/13993003.01347-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36041750 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources